Choosing a buyer for your GP practice: frequently asked questions
Three main buyer types operate in the Australian GP practice market: corporate consolidators, GP group buyers, and internal successors. Each applies different valuation assumptions, deal structures and post-sale management approaches. The buyer type also shapes post-settlement working conditions for owners who remain in the practice. These differences affect both price and day-to-day working life after settlement.
What are the main types of GP practice buyers in Australia?
Three main types operate in the Australian market: corporate consolidators (including private equity-backed groups), GP group buyers (practices or partnerships acquiring additional sites), and internal successors (associate or partner GPs buying out the principal). Each applies different valuation frameworks, deal structures and post-sale governance. Corporate buyers move fastest (three to six months from due diligence to settlement). Internal succession takes the longest, typically 12 to 24 months for capital arrangement and staged transition.
How do corporate buyers differ from GP group buyers in what they offer?
Corporate buyers state higher multiples but attach more conditions. Their deals typically include earnout components tied to post-sale billing continuity and GP retention, meaning the total price received depends on post-settlement performance. GP group buyers generally offer lower multiples with fewer contingencies and build retention incentives into service agreement terms rather than purchase price conditions. Corporate deals also impose standardised governance, compliance and reporting requirements across their network of acquired practices.
What is internal succession and how does it affect the sale price?
Internal succession means selling to an associate or partner GP already working in the practice. Multiples typically sit at 2.5–3.5x EBITDA, reflecting the buyer’s capital constraints and the fact that they already know the practice’s weaknesses. Sellers often have a positive disposition toward these buyers, which can also moderate the price achieved. Deals typically involve vendor finance, staged payments over two to five years, and informal rather than formal retention arrangements.
How do I run a sale process rather than just respond to a buyer approach?
Engage advisers before engaging with any buyer. Define what a good outcome looks like across financial and non-financial dimensions before discussions begin. Identify a pool of potential buyers rather than a single party, and maintain competitive tension through to final terms. Without multiple parties at the table there is no price discovery and no leverage over post-settlement terms. A practice owner who responds to a single unsolicited approach effectively allows the buyer to set both price and conditions.
Further reading: Who you sell to matters as much as what you sell for
What is an earn-out and when should I accept one?
An earn-out defers part of the purchase price, tying it to post-sale performance metrics over a defined period of one to five years. It protects the buyer against paying for revenue that does not survive the ownership change. Before accepting one, understand who controls the operational decisions that determine whether targets are met. If the buyer underinvests, restructures the practice or loses key GPs post-sale, the earn-out can fall short through no fault of the seller.
Further reading: Owner clinical time: separating contribution from profit
How does the buyer type affect my working conditions after the sale?
For owners who continue consulting post-sale, the buyer’s management culture determines daily working life. The person who negotiates the deal is rarely the person who manages the acquired practice post-settlement. Corporate buyers apply policies and governance structures across their network. Autonomy, staffing decisions and compliance burden vary significantly between groups. Assessing post-acquisition culture requires speaking directly to GPs in practices the buyer has already acquired, not relying on the pitch from the deal team.
Further reading: Who you sell to matters as much as what you sell for
What does a transition period typically look like in a GP practice sale?
Transition periods of three to five years are common where the owner accounts for a significant share of billings. During this period the owner continues consulting under a facilities and services agreement while the buyer establishes ownership. Patient relationships transfer gradually, replacement GPs are recruited and billing levels stabilise. A clearly documented transition commitment typically produces a higher total purchase price, a larger upfront component and less aggressive earn-out terms than an immediate exit.
Further reading: Owner clinical time: separating contribution from profit
How do I evaluate a buyer’s management culture before signing?
Speak to GPs currently working in practices the buyer has already acquired, not those recommended by the buyer. Ask about day-to-day clinical autonomy, administrative burden, staffing decisions and whether the post-acquisition experience matched what was represented during the deal. If possible, speak to a GP owner who considered selling to this buyer and decided not to, and find out why. Review governance provisions in the contract before commercial pressure to close has built up.
Further reading: Who you sell to matters as much as what you sell for
What is a vendor finance arrangement and when is it used in GP practice sales?
Vendor finance means the seller provides financing to the buyer as part of the deal structure, deferring receipt of part of the purchase price. It is most common in internal succession scenarios where the incoming GP buyer cannot access full external financing. The seller is repaid over an agreed period, typically two to five years, with interest. Vendor finance increases counterparty risk for the seller and should be structured with appropriate security arrangements agreed with a lawyer before signing.
What is the difference between a clean exit and a phased exit from my practice?
A clean exit means the owner leaves at or shortly after settlement. Revenue from their clinical sessions stops immediately, so more of the purchase price shifts to contingent payments and the upfront component is lower. A phased exit means remaining in the practice for a defined period post-sale, reducing buyer risk. Phased exits typically produce a higher total purchase price, a larger upfront payment and less aggressive earn-out terms, in exchange for a longer commitment to the practice.
Further reading: Owner clinical time: separating contribution from profit
How does my stated reason for selling affect the price a buyer will offer?
Buyers use your exit rationale to set due diligence scope before opening your financials. A planned retirement at an age-appropriate time signals stability and attracts standard due diligence and full market multiples. Urgency signals such as health events, financial distress or partnership dissolution trigger expanded scrutiny and lower offers. Corporate acquirers systematically identify reasons to adjust price downward. Framing your rationale carefully within bounds of honesty is one of the few pre-sale variables entirely within your control.
Further reading: Does your reason for selling affect what buyers offer for your GP practice?
What does an internal succession involve and why do most of them fail?
Internal succession involves selling to an existing associate, partner or incoming GP rather than an external buyer. Most fail because the parties do not agree a formal valuation methodology, assume goodwill about financing arrangements, and do not document the transaction structure until disputes arise. Incoming owners often lack the capital to match external buyer terms. Without vendor finance, staged purchase arrangements or external lending, the deal stalls. Practices that begin internal succession planning two to three years ahead and document every step have materially better completion rates.
How should an internal GP practice sale be structured?
Structuring options include a staged equity transfer, a unit trust with periodic unit purchases, a company share sale, or a business asset sale with vendor finance. Each has different tax, stamp duty and lending implications. The structure should be determined by an accountant and lawyer with experience in medical practice transactions, not adapted from a generic business sale template. Common errors include underpricing the initial stake to make it accessible, then discovering the remaining tranches are unaffordable under the agreed formula.